DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Waardenburg syndrome — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleWaardenburg syndrome maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for waardenburg syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
endothelin 3 (EDN3) — EDN3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6IGK · 2.0 Å · ligand (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate (OLC). Experimental structure, not a prediction.
What the evidence adds up to
A 1979 review notes that Waardenburg syndrome, first clearly defined in 1951, is inherited in an autosomal dominant pattern and that about 20% of affected individuals are deaf. The syndrome consists of six major features that can appear in any combination and to any degree in the affected person. A 2012 case report describes a six-year-old boy with Waardenburg syndrome type 2 (WS2), one of four clinical types, and states that the condition is rare, with few reports in the otological literature. The report does not provide any treatment or outcome data for the child.
A separate 2012 study investigated the functional effect of nine mutations in the MITF, PAX3, and SOX10 genes that cause Waardenburg syndrome. The abstract states the objective was to study the molecular mechanism of the syndrome, but the full text is not available in the provided excerpt, so no results, response rates, or survival data can be reported from this work.
No drug, intervention, or therapy is mentioned in any of the three abstracts. There is no evidence of any treatment being tested or any clinical outcome measured beyond the description of the genetic and clinical features of the syndrome. What is missing is any clinical trial, any tested drug, any patient stratification, and any funding directed toward a therapeutic intervention for Waardenburg syndrome.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Indian Journal of Otology · 2012 · 0 citations
Waardenburg syndrome 2
AbstractWaardenburg syndrome (WS) is a rare disease characterised by sensorineural deafness in association with oculocutaneous pigmentary anomalies and dystopia canthorum. In this article, we report a 6-year-old boy with WS2, one of four clinical types of WS, for its rarity and relative paucity of reports in the otological literature. We also review the relevant literature of this rare disorder.
Waardinburg syndrome — inherited deafness with pigmentary involvement
AbstractThe Waardenburg syndrome was first clearly defined in 1951. The major clinical importance lies in the fact that about 20% of affected individuals are deaf. Furthermore, because the condition is inherited autosomal dominantly, there is a risk of the disorder being handed down from generation to generation. The syndrome consists of six major features which may appear in any combination and to any degree in the affected individual.
German Medical Science (German Research Foundation) · 2012 · 0 citations · open access
Functional analysis of Waardenburg Syndrome-associated mutations
AbstractObjective: To investigate effect of mutations of MITF, PAX3, and SOX10 causing Waardenburg Syndrome (WS) on their wild type (WT) protein and further study molecular mechanism of WS. Methods: we performed studies of the nine mutations (H80D and H186fs in PAX3 with WS1, R217I and T192fs in MITF with[for full text, please go to the a.m. URL]
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
